Submit News | Submit Press Releases | Create Profile | News Pricing | Become an Affiliate | RSS | Alerts | WooEB    
Business News

QLTI Jumps On Settlement - sourced PicksThatMove.com

QLT Inc., Repros Therapeutics Inc.

Calgary, AB 11/25/2009 07:58 PM GMT (TransWorldNews)

 

Calgary, Alberta - PicksThatMove.com opines promising trading opportunities with likely potential for gain. The companies we follow have favourable revenue models for business development at upward cycles.  Please visit us at PicksThatMove.com to view more of our profiled stocks.

 

QLTI Jumps On Settlement

 

The hot stock information of the day includes:  RPRX, QLTI

 

QLT Inc. (USA) (NASDAQ:QLTI) rose 15.97% up to $4.37 on news QLT has settled a lawsuit brought by Massachusetts General Hospital.  QLT will pay $20 million to the Massachusetts General Hospital which has agreed to drop their lawsuit against QLT. QLT developed Visudyne, which treats age-related vision conditions, in cooperation with Massachusetts General and the Massachusetts Eye and Ear Infirmary.  Massachusetts General launched its suit in February on grounds that it was entitled to higher revenues from Visudyne sales. Headquartered in Vancouver, Canada, QLT Inc is a biopharmaceutical company which discovers, develops, and commercializes pharmaceutical products, primarily for ophthalmology and eye care.  The company’s Visudyne photosensitizer treats eye disease, known as age related macular degeneration; and severe near-sightedness, and presumed ocular histoplasmosis or other eye diseases.

 

Repros Therapeutics Inc. (NASDAQ:RPRX) gained 16.90% up to $0.822 on no news with 1,048,129 shares moving this afternoon. Based in The Woodlands, Texas, Repros Therapeutics is a development-stage biopharmaceutical company developing drug therapies for the treatment of serious female pelvic conditions, such as treatment of uterine fibroids, anaemia associated with excessive menstrual bleeding relating to uterine fibroids, and anaemia associated with uterine fibroids and endometriosis.  Repros Therapeutics has three late stage drug candidates in trials.

 

To be kept up to date on all of our hot stock information join us at Picks That Move.

 

About PicksThatMove.com:

 

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

 

 

 

info@picksthatmove.com
picksthatmove.com

Empty Image

Empty Image

   |    View Profile

Visit Blogs                           |    Bookmark and Share

Empty Image

NEWS ALERTS

Receive alerts for RPRX to your inbox. Sign up for TransWorldNews Alerts

Empty Image